You will assess and revamp the IAM strategy across products, platforms, and infrastructure to support a zero-trust security model. Additionally, you will act as a technical advisor to cross-functional teams to ensure IAM principles are integrated into the broader security architecture.
You will lead the clinical pharmacology and pharmacometrics strategy for rare disease and oncology programs, including designing clinical studies and overseeing modeling and simulation. You will also serve as the primary clinical pharmacology representative for regulatory interactions and cross-functional team collaborations.
You will lead the clinical pharmacology and pharmacometrics strategy for oncology and rare disease programs, overseeing modeling and simulation to support drug development. You will also design clinical studies and serve as the primary expert during regulatory interactions and submissions.
You will develop and lead integrated Medical Affairs strategies for priority assets, including evidence generation, scientific narrative, and stakeholder engagement. Additionally, you will build and scale the Medical Affairs organization to support Recursion's growth from clinical development through launch readiness.
The Executive Director will define and drive asset strategy for clinical programs in oncology and immunology, translating scientific complexity into strategic clarity. They will partner across functional lines to ensure resource allocation supports the most impactful programs and leverages proprietary computational insights.
You will join a cross-functional team to advance frontier AI research and end-to-end applications in drug discovery and translation. Your work will focus on developing a unifying biomedical world model to accelerate scalable biomedical discovery.
Interns will have the opportunity to contribute to impactful work that changes lives. They will be part of a team that values integrity, collaboration, and innovation.
